ExperimentalDICENCT03234790
Human Study to Develop a Signature of Occupational Diesel Exhaust Exposure
A study testing Filtered Air Exposure and Diesel Exhaust Exposure in people with Experimental, run by University of British Columbia at 1 site in Canada.
Trial summary
Strong scientific understanding of how emissions from diesel engines impact the lungs could improve policies and regulations protecting workers exposed to diesel exhaust. Accordingly, we are recruiting healthy volunteers who are non-smokers to participate in our study. Read more about this study
- Who is it for?
- Ages 19 to 49 yearsHealthy volunteers can take part
- Conditions the study is for
- Experimental
- What is being tested?
- Filtered Air Exposure and Diesel Exhaust Exposure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteCanada
- Study dates
- 27 Sep 2017to 16 Jul 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 49 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- 19-49 years
- Non-smokers
- No physician diagnosed asthma
Who cannot join
- Pregnant/breastfeeding
- Using inhaled corticosteroids
- Co-existing medical conditions (as assessed by the primary investigator)
- Taking part in another study that involves taking medications.
- Abnormal lung function based on screening spirometry
- Cardiac diagnosis or arrhythmia is discovered during the screening process
Trial locations and contacts
1 site in 1 country.
Canada1 site
University of British Columbia - VGH site
Vancouver, British Columbia, V5Z 1M9
About this study
Official title: A Controlled Dose-Response Human Study to Develop a Signature of Occupational Diesel Exhaust Exposure
Strong scientific understanding of how emissions from diesel engines impact the lungs could improve policies and regulations protecting workers exposed to diesel exhaust. Accordingly, we are recruiting healthy volunteers who are non-smokers to participate in our study. Volunteers sit in a room for four hours and breathe either clean filtered air or air that contains pollution at various concentrations similar to occupational settings such as bus and ferry terminals where diesel engines are used. A respirologist assesses the volunteer's lung health and clinical samples are taken. We are equipped with advanced molecular biology tools to measure different molecules and compare samples from our volunteer subjects following exposure to clean air or diesel exhaust. Our research aim is to find a simple, clinically relevant strategy that can be used to measure the impact of diesel exhaust on workers' lung health. This knowledge will empower regulators, companies, and ultimately workers to better manage their health risks. Our research aims to provide specific data to help regulators to make informed decisions about the risks of diesel exhaust exposure.
Read the detailed description
- Purpose: Over 100,000 employees in Alberta are inadvertently exposed to diesel exhaust at work because of wide use of diesel engines in vehicles and machines used in road construction, trucking, forestry, oil extraction and mineral mining. Although ambient air monitoring of DE exposure exists in some occupational settings, ambient air monitoring depends heavily on surrogate models and may yield a distorted picture of past exhaust exposure. Thus, a clear exposure limit based on bio-monitoring is needed to adequately protect the workers.
- Objective: Our research aims to establish the relationship between exposure concentration and biological effect as an aid to determination of reference ranges for acceptable exposure.
- Hypotheses and Aims: Hypothesis 1: Diesel exhaust (DE) inhalation elicits a characteristic protein output, in a dose-dependent manner. Aim 1. Demonstrate, using a proteomic analysis of serum and urine, a signature that acutely increases in response to a range of occupationally relevant DE concentrations. Hypothesis 2: DE inhalation increases concentrations of metabolites of polyaromatic hydrocarbons (PAH) in urine, in a dose-dependent manner. Aim 2. Ascertain the range of PAH metabolites accumulation in urine following acute exposure to a range of occupationally relevant DE concentrations. Hypothesis 3: DE inhalation alters the airway responsiveness to a contractile stimulus, in a dose-dependent manner, and that alteration is associated with changes in a combined proteomic/PAH-metabolomic signature. Aim 3: Determine the dose-response slope to methacholine, in response to a range of occupationally relevant DE concentrations, and correlate changes in this slope to changes in proteins and metabolites. Additionally, we aim to establish the relationship between a range of controlled DE exposure concentrations and sleep quality and breathing in sleep through the sub-study component.
- Justification: Our work will inform decision makers and stakeholders in creating evidence-based policies to limit occupational diesel exhaust exposure based on relevant biology.
- Research Method: This is an order-randomized, double-blinded, crossover human exposure study. This project aims to determine markers of DE exposure that can be used in an occupational setting. Therefore, we will use a range of occupational exposure levels to appropriately contextualize our results. For this, 20 healthy participants will be exposed to a control condition and 3 different levels of DE concentration, each for a period of 4 hours, in a randomized order. Each exposure will be separated by a washout period of two weeks. The levels will be DE titrated to 20, 50 and 150 ug/m3 PM2.5, and the control exposure will be filtered air (FA). Participants will undergo a methacholine challenge and will provide urine and blood samples before and after exposures to analyze lung function and biological responses. If participants consent to participation in the sleep sub-study, they will be provided with additional questionnaires throughout their visits pertaining to their sleep quality. The participants will be provided with an Alice NightOne sleep monitor and instructions on how to operate the equipment. The sleep monitor will be hooked up by the participant at home when they are about to sleep, following an exposure, and will monitor their sleep patterns for that night.
- Statistical Analysis:
First, the changes in clinical parameters (methacholine PC20 and dose response slope) and serum blood protein abundance between pre- and post-exposure will be determined. These 'delta' values will be statistically compared across exposures using linear mixed effects models using R program, as outlined in our previous publications from similarly-designed protocols from our group. Values of p<0.05 will be considered significant throughout, with adjustments for multiple comparisons. Although the 2-week washout period is intended to minimize the likelihood of carryover effects, we will formally assess for this by including a term for order of exposures in the models.
Analyses for the sleep component will be performed at the Hospital of Ottawa and will be completed through a linear or logistic mixed effects model, as applicable using the R program. Similar methods to data collected from the main study. Data interpretation will be completed through a software algorithm on the local server.
- Conditions
- Experimental
- Being tested
- Filtered Air Exposure, Diesel Exhaust Exposure
- Keywords
- Diesel Exhaust, Air Pollution, Airway Responsiveness, Proteomics, Urine PAH Metabolites
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Filtered Air ExposureOther
Exposure to Filtered air
Diesel Exhaust ExposureOther
Diesel exposure to different concentrations at different times: 20, 50 and 150ug/m3
| Study group | Role | What they receive |
|---|---|---|
| Filtered Air Exposure | Active comparator | Exposure for 4 hours to filtered air Receives: Other: Filtered Air Exposure |
| Diesel Exhaust Exposure | Experimental | Volunteers exposed to different concentrations of diesel exhaust Receives: Other: Diesel Exhaust Exposure |
What is being measured
The primary outcome is the main question the study is designed to answer.
Serum proteome in response to DE exposure
Serum from each experimental condition will be analyzed by liquid chromatography-mass spectrometry (LC-MS/MS) to observe any changes between the baseline and listed time points
Measured: 4 hours & 24 hours
Secondary outcomes (3)
Urine proteins in response to DE exposure
Urine from each experimental condition will be analyzed by liquid mass chromatography to observe any changes between the baseline and listed time points.
Measured: 4 hours & 24 hours
Polycyclic Aromatic Hydrocarbons (PAH) metabolites in response to DE exposure
PAH metabolites in urine samples will be analyzed by HPLC to observe any changes between the baseline and listed time points.
Measured: 4 hours & 24 hours
Sleep quality
Sleep quality will be assessed by level 3 overnight monitor and questionnaires
Measured: baseline versus 24 hours post-exposure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jul 2017
- Study start27 Sep 2017
- Primary completion16 Jul 2021
- Study completion16 Jul 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for ExperimentalStudies of the same condition, open and under way.
- More trials run by University of British ColumbiaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of British Columbia
- Sponsor type
- University, hospital or other
- Collaborators
- Government of Alberta, Ottawa Hospital Research Institute
- Responsible party
- Principal investigator, Christopher Carlsten, University of British Columbia
- Investigators
- Christopher Carlsten, MD, MPH, Principal investigator, University of British Columbia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03234790
- Sponsor's protocol ID
- H16-03053
- Acronym
- DICE
- Status last verified
- Oct 2021
- First submitted
- 25 Jul 2017
- Last updated
- 2 Nov 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Guest PC, Gottschalk MG, Bahn S. Proteomics: improving biomarker translation to modern medicine? Genome Med. 2013 Feb 27;5(2):17. doi: 10.1186/gm421. eCollection 2013. No abstract available.
PubMed 23445684Huang W, Smith TJ, Ngo L, Wang T, Chen H, Wu F, Herrick RF, Christiani DC, Ding H. Characterizing and biological monitoring of polycyclic aromatic hydrocarbons in exposures to diesel exhaust. Environ Sci Technol. 2007 Apr 15;41(8):2711-6. doi: 10.1021/es062863j.
PubMed 17533828Morgott DA. Factors and Trends Affecting the Identification of a Reliable Biomarker for Diesel Exhaust Exposure. Crit Rev Environ Sci Technol. 2014 Aug;44(16):1795-1864. doi: 10.1080/10643389.2013.790748.
PubMed 25170242Orach J, Rider CF, Yuen ACY, Schwartz C, Mookherjee N, Carlsten C. Controlled Diesel Exhaust Exposure Induces a Concentration-dependent Increase in Airway Inflammation: A Clinical Trial. Ann Am Thorac Soc. 2023 Jun;20(6):834-842. doi: 10.1513/AnnalsATS.202209-762OC.
PubMed 36930796
Study at a glance
From the registry record, last updated by the sponsor on 2 Nov 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Controlled Dose-Response Human Study to Develop a Signature of Occupational Diesel Exhaust Exposure
- ClinicalTrials.gov ID
- NCT03234790
- Acronym / sponsor ID
- DICE / H16-03053
- Conditions
- Experimental
- Keywords
- Diesel Exhaust, Air Pollution, Airway Responsiveness, Proteomics, Urine PAH Metabolites
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- University of British ColumbiaUniversity, hospital or other
- Collaborators
- Government of Alberta, Ottawa Hospital Research Institute
- Study start
- 27 Sep 2017 (actual)
- Primary completion
- 16 Jul 2021 (actual)
- Study completion
- 16 Jul 2021 (actual)
- First posted
- 31 Jul 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Strong scientific understanding of how emissions from diesel engines impact the lungs could improve policies and regulations protecting workers exposed to diesel exhaust. Accordingly, we are recruiting healthy volunteers who are non-smokers to participate in our study. Volunteers sit in a room for four hours and breathe either clean filtered air or air that contains pollution at various concentrations similar to occupational settings such as bus and ferry terminals where diesel engines are used. A respirologist assesses the volunteer's lung health and clinical samples are taken. We are equipped with advanced molecular biology tools to measure different molecules and compare samples from our volunteer subjects following exposure to clean air or diesel exhaust. Our research aim is to find a simple, clinically relevant strategy that can be used to measure the impact of diesel exhaust on workers' lung health. This knowledge will empower regulators, companies, and ultimately workers to better manage their health risks. Our research aims to provide specific data to help regulators to make informed decisions about the risks of diesel exhaust exposure.
Detailed description
- Purpose: Over 100,000 employees in Alberta are inadvertently exposed to diesel exhaust at work because of wide use of diesel engines in vehicles and machines used in road construction, trucking, forestry, oil extraction and mineral mining. Although ambient air monitoring of DE exposure exists in some occupational settings, ambient air monitoring depends heavily on surrogate models and may yield a distorted picture of past exhaust exposure. Thus, a clear exposure limit based on bio-monitoring is needed to adequately protect the workers.
- Objective: Our research aims to establish the relationship between exposure concentration and biological effect as an aid to determination of reference ranges for acceptable exposure.
- Hypotheses and Aims: Hypothesis 1: Diesel exhaust (DE) inhalation elicits a characteristic protein output, in a dose-dependent manner. Aim 1. Demonstrate, using a proteomic analysis of serum and urine, a signature that acutely increases in response to a range of occupationally relevant DE concentrations. Hypothesis 2: DE inhalation increases concentrations of metabolites of polyaromatic hydrocarbons (PAH) in urine, in a dose-dependent manner. Aim 2. Ascertain the range of PAH metabolites accumulation in urine following acute exposure to a range of occupationally relevant DE concentrations. Hypothesis 3: DE inhalation alters the airway responsiveness to a contractile stimulus, in a dose-dependent manner, and that alteration is associated with changes in a combined proteomic/PAH-metabolomic signature. Aim 3: Determine the dose-response slope to methacholine, in response to a range of occupationally relevant DE concentrations, and correlate changes in this slope to changes in proteins and metabolites. Additionally, we aim to establish the relationship between a range of controlled DE exposure concentrations and sleep quality and breathing in sleep through the sub-study component.
- Justification: Our work will inform decision makers and stakeholders in creating evidence-based policies to limit occupational diesel exhaust exposure based on relevant biology.
- Research Method: This is an order-randomized, double-blinded, crossover human exposure study. This project aims to determine markers of DE exposure that can be used in an occupational setting. Therefore, we will use a range of occupational exposure levels to appropriately contextualize our results. For this, 20 healthy participants will be exposed to a control condition and 3 different levels of DE concentration, each for a period of 4 hours, in a randomized order. Each exposure will be separated by a washout period of two weeks. The levels will be DE titrated to 20, 50 and 150 ug/m3 PM2.5, and the control exposure will be filtered air (FA). Participants will undergo a methacholine challenge and will provide urine and blood samples before and after exposures to analyze lung function and biological responses. If participants consent to participation in the sleep sub-study, they will be provided with additional questionnaires throughout their visits pertaining to their sleep quality. The participants will be provided with an Alice NightOne sleep monitor and instructions on how to operate the equipment. The sleep monitor will be hooked up by the participant at home when they are about to sleep, following an exposure, and will monitor their sleep patterns for that night.
- Statistical Analysis:
First, the changes in clinical parameters (methacholine PC20 and dose response slope) and serum blood protein abundance between pre- and post-exposure will be determined. These 'delta' values will be statistically compared across exposures using linear mixed effects models using R program, as outlined in our previous publications from similarly-designed protocols from our group. Values of p<0.05 will be considered significant throughout, with adjustments for multiple comparisons. Although the 2-week washout period is intended to minimize the likelihood of carryover effects, we will formally assess for this by including a term for order of exposures in the models.
Analyses for the sleep component will be performed at the Hospital of Ottawa and will be completed through a linear or logistic mixed effects model, as applicable using the R program. Similar methods to data collected from the main study. Data interpretation will be completed through a software algorithm on the local server.
Study design
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Filtered Air Exposure | Active comparator | Other: Filtered Air ExposureExposure for 4 hours to filtered air |
| Diesel Exhaust Exposure | Experimental | Other: Diesel Exhaust ExposureVolunteers exposed to different concentrations of diesel exhaust |
Who may qualify
- Ages
- 19 to 49 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- 19-49 years
- Non-smokers
- No physician diagnosed asthma
Key exclusion criteria (6 listed)
- Pregnant/breastfeeding
- Using inhaled corticosteroids
- Co-existing medical conditions (as assessed by the primary investigator)
- Taking part in another study that involves taking medications.
- Abnormal lung function based on screening spirometry
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Filtered Air ExposureExposure to Filtered air | Other | Filtered Air Exposure |
| Diesel Exhaust ExposureDiesel exposure to different concentrations at different times: 20, 50 and 150ug/m3 | Other | Diesel Exhaust Exposure |
Primary outcome
Serum proteome in response to DE exposure
Time frame: 4 hours & 24 hours
Serum from each experimental condition will be analyzed by liquid chromatography-mass spectrometry (LC-MS/MS) to observe any changes between the baseline and listed time points
3 secondary outcomes
Urine proteins in response to DE exposure
Time frame: 4 hours & 24 hours
Polycyclic Aromatic Hydrocarbons (PAH) metabolites in response to DE exposure
Time frame: 4 hours & 24 hours
Sleep quality
Time frame: baseline versus 24 hours post-exposure
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Nov 2021.
- Background: PubMed 23445684Guest PC, Gottschalk MG, Bahn S. Proteomics: improving biomarker translation to modern medicine? Genome Med. 2013 Feb 27;5(2):17. doi: 10.1186/gm421. eCollection 2013. No abstract available.
- Background: PubMed 17533828Huang W, Smith TJ, Ngo L, Wang T, Chen H, Wu F, Herrick RF, Christiani DC, Ding H. Characterizing and biological monitoring of polycyclic aromatic hydrocarbons in exposures to diesel exhaust. Environ Sci Technol. 2007 Apr 15;41(8):2711-6. doi: 10.1021/es062863j.
- Background: PubMed 25170242Morgott DA. Factors and Trends Affecting the Identification of a Reliable Biomarker for Diesel Exhaust Exposure. Crit Rev Environ Sci Technol. 2014 Aug;44(16):1795-1864. doi: 10.1080/10643389.2013.790748.
- Derived from this study: PubMed 36930796Orach J, Rider CF, Yuen ACY, Schwartz C, Mookherjee N, Carlsten C. Controlled Diesel Exhaust Exposure Induces a Concentration-dependent Increase in Airway Inflammation: A Clinical Trial. Ann Am Thorac Soc. 2023 Jun;20(6):834-842. doi: 10.1513/AnnalsATS.202209-762OC.
- Individual participant dataSharing planned: No
Related trials for Experimental
Not yet recruiting
Human Experimental Models of Pain (HEMP)
Acute Pain
RecruitingPhase 1/2
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
Amyotrophic Lateral Sclerosis
Not yet recruitingObservational study
Systematic Intraoperative Cell Salvage in On-Pump Cardiac Surgery Within a Mature Patient Blood Management Programme
Cardiac Surgical Procedures, Blood Transfusion
Active, not recruitingPhase 2
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Carcinoma, Non-Small-Cell Lung
Active, not recruitingPhase 2
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Christopher Carlsten, MD, MPH principal investigator
University of British Columbia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Filtered Air Exposure and Diesel Exhaust Exposure in people with Experimental, run by University of British Columbia at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Serum proteome in response to DE exposure (time frame: 4 hours & 24 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03234790, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2021.